Metsera

Metsera CapEx/D&A

Delisted

CapEx to Depreciation Ratio of Metsera (MTSR) as of Nov 4, 2026.

CapEx/D&A

-

Last updated:

CapEx to Depreciation Ratio of Metsera is 2026 - . CapEx to Depreciation Ratio of Metsera was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Metsera Stock analysis

What does Metsera do? Metsera Inc. is a clinical stage biopharmaceutical company based in New York City, operating in the Health Care sector with a focus on Biotechnology. The company develops next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for treating obesity and related conditions. Utilizing its proprietary MINT peptide library, HALO half-life extension platform, and MOMENTUM oral delivery system, Metsera has a pipeline including MET-097i, MET-233i, and MET-224o, targeting various obesity treatments with differentiated approaches. Listed on 31 January 2025, the company employs 82 staff. Metsera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Metsera stock

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Metsera since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Metsera with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Metsera

All Key Metrics — Metsera